Literature DB >> 8632705

Tissue distribution of ibogaine after intraperitoneal and subcutaneous administration.

L B Hough1, S M Pearl, S D Glick.   

Abstract

The distribution of the putative anti-addictive substance ibogaine was measured in plasma, brain, kidney, liver and fat after ip and sc administration in rats. One hr after ip dosing (40 mg/kg), drug levels ranged from 106 ng/ml (plasma) to 11,308 ng/g (fat), with significantly higher values after sc administration of the same dose. Drug levels were 10-20 fold lower 12 hr after the same dose. These results suggest that: 1) ibogaine is subject to a substantial "first pass" effect after ip dosing, demonstrated by higher drug levels following the sc route, 2) ibogaine shows a large accumulation in adipose tissue, consistent with its lipophilic nature, and 3) persistence of the drug in fat may contribute to a long duration of action.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8632705     DOI: 10.1016/0024-3205(95)02322-4

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  9 in total

1.  Long-lasting ibogaine protection against NMDA-induced convulsions in mice.

Authors:  M B Leal; D O de Souza; E Elisabetsky
Journal:  Neurochem Res       Date:  2000-08       Impact factor: 3.996

2.  Ibogaine and the dopaminergic response to nicotine.

Authors:  I M Maisonneuve; G L Mann; C R Deibel; S D Glick
Journal:  Psychopharmacology (Berl)       Date:  1997-02       Impact factor: 4.530

Review 3.  The anti-addiction drug ibogaine and the heart: a delicate relation.

Authors:  Xaver Koenig; Karlheinz Hilber
Journal:  Molecules       Date:  2015-01-29       Impact factor: 4.411

4.  A non-hallucinogenic psychedelic analogue with therapeutic potential.

Authors:  Lindsay P Cameron; Robert J Tombari; Ju Lu; Alexander J Pell; Zefan Q Hurley; Yann Ehinger; Maxemiliano V Vargas; Matthew N McCarroll; Jack C Taylor; Douglas Myers-Turnbull; Taohui Liu; Bianca Yaghoobi; Lauren J Laskowski; Emilie I Anderson; Guoliang Zhang; Jayashri Viswanathan; Brandon M Brown; Michelle Tjia; Lee E Dunlap; Zachary T Rabow; Oliver Fiehn; Heike Wulff; John D McCorvy; Pamela J Lein; David Kokel; Dorit Ron; Jamie Peters; Yi Zuo; David E Olson
Journal:  Nature       Date:  2020-12-09       Impact factor: 49.962

Review 5.  Overcoming Depression with 5-HT2A Receptor Ligands.

Authors:  Agata Zięba; Piotr Stępnicki; Dariusz Matosiuk; Agnieszka A Kaczor
Journal:  Int J Mol Sci       Date:  2021-12-21       Impact factor: 5.923

6.  Drug Transporters ABCB1 (P-gp) and OATP, but not Drug-Metabolizing Enzyme CYP3A4, Affect the Pharmacokinetics of the Psychoactive Alkaloid Ibogaine and its Metabolites.

Authors:  Margarida L F Martins; Paniz Heydari; Wenlong Li; Alejandra Martínez-Chávez; Nikkie Venekamp; Maria C Lebre; Luc Lucas; Jos H Beijnen; Alfred H Schinkel
Journal:  Front Pharmacol       Date:  2022-03-04       Impact factor: 5.810

Review 7.  Three Naturally-Occurring Psychedelics and Their Significance in the Treatment of Mental Health Disorders.

Authors:  Nataliya Vorobyeva; Alena A Kozlova
Journal:  Front Pharmacol       Date:  2022-06-28       Impact factor: 5.988

Review 8.  The iboga enigma: the chemistry and neuropharmacology of iboga alkaloids and related analogs.

Authors:  Rishab N Iyer; David Favela; Guoliang Zhang; David E Olson
Journal:  Nat Prod Rep       Date:  2021-03-04       Impact factor: 13.423

9.  Ibogaine Has Sex-Specific Plasma Bioavailability, Histopathological and Redox/Antioxidant Effects in Rat Liver and Kidneys: A Study on Females.

Authors:  Nikola Tatalović; Teodora Vidonja Uzelac; Milica Mijović; Gordana Koželj; Aleksandra Nikolić-Kokić; Zorana Oreščanin Dušić; Mara Bresjanac; Duško Blagojević
Journal:  Life (Basel)       Date:  2021-12-23
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.